Analysts/Institutional Investor Meet/Con. Call Updates

November 05, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Transcript of Earnings Conference call with Analyst / Investor on Financial Results for the second quarter and half year ended on September 30, 2026 Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Transcript of the Earnings Conference call (i.e. post earnings / quarterly call) which was held on Monday, November 02, 2026 at 11:30 a.m. (IST) to discuss the financial results of the Company for the second quarter and half year ended on September 30, 2026. The said transcript is also available on the website of the Company at www.coronaremedies.com You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a “CORONA Remedies Limited 2Q & 1HFY27 Earnings Conference Call” November 02, 2026 E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recording uploaded on the stock exchanges on 2nd November 2026 will prevail MANAGEMENT: MR. NIRAV MEHTA – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – CORONA REMEDIES LIMITED MR. ANKUR MEHTA – JOINT MANAGING DIRECTOR – CORONA REMEDIES LIMITED MR. BHAVIN BHAGAT – CHIEF FINANCIAL OFFICER – CORONA REMEDIES LIMITED SGA, INVESTOR RELATIONSHIP PARTNERS – CORONA REMEDIES LIMITED MODERATOR: MR. UMESH LADDHA -- AMBIT CAPITAL PRIVATE LIMITED. Page 1 of 14 CORONA Remedies Limited November 02, 2026 Moderator: Ladies and gentlemen, good day and welcome to the 2Q and 1HFY27 Earnings Conference Call of CORONA Remedies Limited. Before we begin, I would like to point out that this conference call may contain certain forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as of the date of this call. These statements are not a guarantee of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Umesh Laddha from Ambit Capital Private Limited. Thank you and over to you, Umesh. Umesh Laddha: Good morning, everyone. On behalf of Ambit Capital, we welcome you to the 2Q and 1HFY27 earnings conference call of CORONA Remedies Limited. Today on the call, we are joined by Mr. Nirav Mehta, Managing Director and CEO, Mr. Ankur Mehta, Joint Managing Director, and Mr. Bhavin Bhagat, Chief Financial Officer at CORONA Remedies Limited. We will begin the call with opening remarks from the management, followed by a Q&A session. Thank you, and over to you, Nirav sir. Nirav Mehta: Thank you all for joining us on the 2Q and 1HFY27 earnings conference call for CORONA Remedies Limited. Along with me on the call, I am joined by our Joint Managing Director, Mr. Ankur Mehta, our CFO Mr. Bhavin Bhagat, other members of the senior management team, and Strategic Growth Advisors, our investor relation advisor. We have uploaded our results press release and investor presentation on the stock exchange and on the company's website. I hope everybody has had the opportunity to go through the same. Before we discuss our performance, I would like to share a few thoughts on the Indian pharmaceutical market. The Indian pharmaceutical market continues to show strong momentum, delivering low to mid- double-digit growth since December 2025. As for PharmaTrac, the Indian pharmaceutical market registered its highest-ever monthly growth of 13.5% in September 2026. Interestingly, this growth is increasingly coming from volume along with other growth drivers. Page 2 of 14 CORONA Remedies Limited November 02, 2026 We believe this reflects deep structural strength that will support consistent growth in the coming years. We firmly believe that Indian pharma is a sunrise sector, well positioned for sustained long-term growth. Speaking of CORONA, we are well positioned to capitalize on the long-term structural growth of the Indian pharmaceutical market and our track record gives us confidence in this. We have consistently outperformed the market. As per PharmaTrac, over the last 3 years, CORONA has grown at 1.9 times, the Indian pharmaceutical market. More importantly, this outperformance has been driven by volume growth, new introductions growth and price growth. Our volume growth has been nearly 3.3 times that of the Indian pharmaceutical market, and growth from new introduction stands about 2.2 times, while price growth has been 1.2 times. This reinforces our strategy of outperforming the market by expanding volumes and broadening our product basket. CORONA is now amongst top 15 pharmaceutical companies at 14th rank in the covered market. Overall, CORONA stands at 26th rank in the Indian pharmaceutical market and continues to be one of the fastest-growing companies in the Indian pharmaceutical market. Speaking on our quarterly performance and highlights, we are pleased to report another quarter of strong and consistent performance, with revenue growing by 22% year-on-year in Q2 and similar 22% in H1 FY27. If we remove acquired brand Wokadine, growth was 21.5% in Q2 and 21.5% in H1 FY27. Our India business delivered an impressive 22.9% year-on-year growth in Q2 FY27, significantly outperforming the Indian pharmaceutical market, which grew by around 12% during the same period as per PharmaTrac data. More encouragingly, the chronic segment of Indian pharmaceutical market continues to grow at the faster pace, recording growth of 14.9%, approximately 25% higher than the overall market during the same period. Against this backdrop, our chronic business at CORONA has grown by around 29%, delivering nearly 2x the growth of the corresponding market segment. This sustained outperformance reflects our disciplined execution focused brand-building initiatives and the continued trust and confidence that healthcare professionals place in our products. More importantly, it reinforces our confidence in the strength of our business fundamentals and the sustainability of our long-term growth strategy. Our consistent growth at CORONA rests on four pillars: first, strengthening our core therapies. Second, brand building. Third, disciplined operational excellence; and fourth, investing in future of CORONA. To conclude, I would like to highlight that supported by a diversified portfolio, strong brands, and expanding distribution networks, experienced leadership, and disciplined capital allocation, we remain confident of delivering sustainable growth and profitability. Page 3 of 14 CORONA Remedies Limited November 02, 2026 I would now like to hand over the call over our Chief Financial Officer, Mr. Bhavin Bhagat, to take you through financial and operational performance. Thank you, and over to you, Bhavin bhai. Bhavin Bhagat: Good morning, everyone. Thank you, Nirav bhai. A warm welcome to everyone to our Q2 FY27 earnings call. I will take you through the financial performance for the quarter and H1 FY27. Speaking of performance, revenue for Q2 FY27 stood at INR441 crores versus INR361 crores in Q2 FY26, reflecting a healthy growth of 22.2% YoY revenue growth in Q2. India business contributed 97% of total revenue in Q2 and H1. Revenue growth for India business stood at 22.9% for Q2 FY27 and 22.8% for H1 FY27. E [Showing first 8,000 characters — download PDF for full document]